FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 334:271-272 January 25, 1996 Number 4 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article Related Article by Brugger, W. PubMed Citation

To the Editor: Brugger and coworkers (Aug. 3 issue)¹ suggest that CD34+ hematopoietic progenitor cells expanded ex vivo rapidly reconstitute hematopoiesis after high-dose chemotherapy (1500 mg of etoposide per square meter of body-surface area, 12 g of ifosfamide per square meter, 750 mg of carboplatin per square meter, and 150 mg of epirubicin per square meter). The authors do not show, however, whether the infused stem cells actually participated in the hematopoietic recovery.

In a dose-escalation study involving patients with high-risk lymphoma, my colleagues and I used doxorubicin in a fixed dose of 90 mg per square meter, etoposide in . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.